Lunai Bioworks Inc. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Lunai Bioworks received notice from Nasdaq on October 21, 2026 that it failed to meet minimum stockholders' equity requirement of $2.5M, reporting a stockholders' deficit of $9.0M as of June 30, 2026. The Board approved voluntary delisting on October 22, 2026; trading suspension expected October 30, 2026; Form 25 filing expected November 2, 2026; delisting effective ~November 12, 2026; Form 15 to follow to suspend SEC reporting obligations. Company will not request hearing and does not plan OTC quotation.
Why this rating
Delisting and deregistration eliminates public market access for shareholders; $9M deficit is ~8% of market cap; existential event for public company status.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.